IDSA/SHEA Clostridium difficile Infection - 2018 Update

Clostridium Difficile Infection - 2018 Update

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/55729

Contents of this Issue

Navigation

Page 9 of 15

10 Treatment Table 2. Potential Treatment Agents for Treatment of the Primary C. difficile Infection (CDI) Episode Agent Adult Dose Cost a Initial Treatment Response Recurrence Risk Proven Efficacy Vancomycin 125 mg PO qid × 10 days $$$$ $ (Liq) +++ ++ Fidaxomicin 200 mg PO bid × 10 days $$$$ +++ + Metronidazole 500 mg PO tid × 10 days $ ++ ++ Probable Efficacy Nitazoxanide 500 mg PO bid × 10 days $$ +++ ++ Fusidic acid 250 mg PO tid × 10 days N/A in USA ++ ++ Inadequate Data To Support Efficacy Rifaximin 400 mg PO tid × 10 days $$$ ++ +? Tigecycline 50 mg IV every bid × 10 days $$$$ ++? ? Bacitracin 25,000 units PO qid × 10 days $$ + +? a All prices are estimated in US dollars as quoted from Red Book Online Search, Micromedex Solutions, last accessed on March 10, 2015 or approximated hospital pharmacy pricing (tigecycline, bacitracin). $: $0–100; $$: $101–500; $$$: $501–1000; $$$$: >$1000

Articles in this issue

view archives of IDSA/SHEA Clostridium difficile Infection - 2018 Update - Clostridium Difficile Infection - 2018 Update